These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7802113)

  • 21. [Cost-effectiveness of Antipsychotics in the Maintenance Treatment of Schizophrenia in Colombia].
    Quitian Reyes H; Arciniegas Barrera JA; Bohórquez Peñaranda A; Gómez Restrepo C
    Rev Colomb Psiquiatr; 2016; 45(2):67-74. PubMed ID: 27132755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.
    Ginsberg G; Shani S; Lev B
    Pharmacoeconomics; 1998 Feb; 13(2):231-41. PubMed ID: 10178649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Looking beyond the formulary budget in cost-benefit analysis.
    Cohen LJ
    Am J Manag Care; 1997 Feb; 3 Suppl():S11-7. PubMed ID: 10180337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
    Polsky D; Doshi JA; Bauer MS; Glick HA
    Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Where to position clozapine: re-examining the evidence.
    Agid O; Foussias G; Singh S; Remington G
    Can J Psychiatry; 2010 Oct; 55(10):677-84. PubMed ID: 20964947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clozapine: progress in treating refractory schizophrenia.
    Hirsch SR; Puri BK
    BMJ; 1993 May; 306(6890):1427-8. PubMed ID: 8518636
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia.
    Jonsson D; Wålinder J
    Acta Psychiatr Scand; 1995 Sep; 92(3):199-201. PubMed ID: 7484198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient response and resource management: another view of clozapine treatment of schizophrenia.
    Carpenter WT; Conley RR; Buchanan RW; Breier A; Tamminga CA
    Am J Psychiatry; 1995 Jun; 152(6):827-32. PubMed ID: 7755110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec.
    Latimer E; Wynant W; Clark R; Malla A; Moodie E; Tamblyn R; Naidu A
    Clin Schizophr Relat Psychoses; 2013 Apr; 7(1):33-41. PubMed ID: 23367500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
    Rosenheck R; Cramer J; Xu W; Thomas J; Henderson W; Frisman L; Fye C; Charney D
    N Engl J Med; 1997 Sep; 337(12):809-15. PubMed ID: 9295240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
    Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
    J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Business Case for Expanded Clozapine Utilization.
    Gören JL; Rose AJ; Smith EG; Ney JP
    Psychiatr Serv; 2016 Nov; 67(11):1197-1205. PubMed ID: 27301766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].
    Geronimi-Ferret D; Lesay M; Barges-Bertocchio MH; Cornet-Bonnefont M; Robert H
    Encephale; 1997 Sep; 23 Spec No 4():24-31. PubMed ID: 9417402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initiating clozapine treatment in the outpatient clinic: service utilization and cost trends.
    Luchins DJ; Hanrahan P; Shinderman M; Lagios L; Fichtner CG
    Psychiatr Serv; 1998 Aug; 49(8):1034-8. PubMed ID: 9712208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
    Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
    Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
    Layton S; Barbeau M
    Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clozapine: indications and implications for treatment.
    Smith L
    Nurs Times; 1995 Jul 26-Aug 1; 91(30):40-1. PubMed ID: 7644370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clozapine revisited: Impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid.
    Thomas KL; Jiang Y; McCombs JS
    Ann Clin Psychiatry; 2015 May; 27(2):90-9. PubMed ID: 25696785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interpretation of analysis.
    Heller JG
    Can J Clin Pharmacol; 2002; 9(3):129, 153; author reply 153. PubMed ID: 12474874
    [No Abstract]   [Full Text] [Related]  

  • 40. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
    Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
    Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.